Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis

Meresman, Gabriela Fabiana; Bilotas, Mariela Andrea; Abello, V.; Buquet, Ricardo; Tesone, Marta; Sueldo, Carlos

doi:10.1016/j.fertnstert.2005.01.137

Cited by 45 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We decided to compare two monophasic pills containing desogestrel and gestodene, respectively, because they are the only OCs used in European studies dealing with this topic. Moreover, according to some authors [38], the use of desogestrel showed a significant decrease in cell proliferation and an increased apoptosis in the ectopic endometrial tissue. Another study on OCs containing gestodene showed a decrease in aromatase expression in the eutopic endometrium of patients with endometriosis [39].…”

Section: Discussionmentioning

confidence: 93%

Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?

Cucinella

Granese²,

Calagna

et al. 2013

Arch Gynecol Obstet

View full text Add to dashboard Cite

Objective The primary aim of the study was to analyze the endometrioma recurrence rate in patients who underwent laparoscopic excision followed by postoperative longterm regimen of oral contraceptives (OCs). Materials and methods 168 patients who underwent a conservative laparoscopic surgery for endometrioma, during the period between September 2009 and August 2010 in three university hospitals were studied. A long-term OCs therapy was offered to all women following surgery. Patients were randomly divided into three groups according to different progestins used (desogestrel, gestodene, dienogest). Women who refused a postoperative hormonal therapy served as control. Follow-up visits and transvaginal scan were planned at 1, 3, 6, 12, and 24 months after surgery. All patients who showed an ultrasound persistence of the endometrioma at 1 month follow-up were excluded from clinical analysis.Results Of the 168 patients, 131 completed the 24 months follow-up. Endometrioma recurrence was found in 21 (12.5 %) of all patients, it was unilateral in 17 cases while bilateral in 4 cases. The rate of recurrent endometrioma was statistically significant in non-users compared to the long-term OCs treated patients. Conclusion The current data suggest the usefulness of long-term OCs regimen after conservative surgery for the prevention of ovarian endometrioma recurrence. As a statistical significant difference could not be observed between OCs groups, further study on the individual molecules is required in order to really understand the effect of each of them.

show abstract

Section: Discussionmentioning

confidence: 93%

Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?

Cucinella

Granese²,

Calagna

et al. 2013

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

“…In this sense, two aromatase inhibitors, letrozole and anastrozole, have also been tested in vitro and in vivo in our laboratory and demonstrated to have antiproliferative and proapoptotic effects (Meresman et al 2005, Bilotas et al 2010.…”

Section: Introductionmentioning

confidence: 99%

Anastrozole and celecoxib for endometriosis treatment, good to keep them apart?

et al. 2013

View full text Add to dashboard Cite

Endometriosis is a benign gynecological disease. Cyclooxygenase-2 (COX-2) and aromatase proteins have been shown to be overexpressed in eutopic endometrium from women suffering from this disease compared to disease-free women. Furthermore, inhibition of these molecules individually was demonstrated to have antiproliferative and proapoptotic effects both in vitro and in vivo in several models. In this study, the effect of combining celecoxib, a selective COX-2 inhibitor, and anastrozole, an aromatase inhibitor, on the implantation and growth of endometriotic like lesions in a murine model of endometriosis was evaluated. Endometriosis was surgically induced in female BALB/c mice. After 28 days of treatment with celecoxib, anastrozole, or their combination, animals were killed and lesions were counted, measured, excised, and fixed. Immunohistochemistry for proliferating cell nuclear antigen and CD34 was performed for assessment of cell proliferation and vascularization. TUNEL technique was performed for apoptosis evaluation. Celecoxib was the only treatment to significantly reduce the number of lesions established per mouse, their size and vascularized area. In addition, cell proliferation was significantly diminished and apoptosis was significantly enhanced by both individual treatments. When the therapies were combined, they reversed their effects. These results confirm that celecoxib and anastrozole separately decrease endometriotic growth, but when combined they might have antagonizing effects.

show abstract

“…A prospective study done on eutopic endometrial cell cultures from patients with endometriosis discovered that the use of letrozole and anastrozole showed positive result in rendering endometriotic cell proliferation. There were significantly high levels of apoptosis observed in the cell cultures as well, suggesting the potential role of aromatase inhibitor as one of the therapeutic options in endometriosis [55].…”

Section: Aromatase Inhibitor In Postmenopausal Endometriosismentioning

confidence: 95%